Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New scan could spot lung cancer return sooner

NCT ID NCT02821936

First seen Jan 04, 2026 · Last updated Jun 19, 2026 · Updated 26 times

Summary

This study looked at whether a special type of PET scan, called parametric imaging, can better predict if lung cancer will come back within a year after treatment. Forty patients with non-small cell lung cancer who were getting radiation and chemotherapy had two of these scans. The goal was to see if this method is more accurate than a standard PET scan for spotting cancer recurrence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • APHM

    Marseille, 13000, France

  • Centre Henri Becquerel

    Rouen, 76000, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a more accurate way to predict lung cancer recurrence, helping doctors decide if treatment adjustments are needed.

What could go wrong

This is a small, early-stage study with only 40 participants. It is not testing a new treatment, only a new imaging method, so it may not change patient care directly.

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.